Tags

Type your tag names separated by a space and hit enter

Dapsone as treatment adjunct in ARDS.
Exp Lung Res. 2020 May - Jun; 46(5):157-161.EL

Abstract

Multiple pharmacological interventions tested over the last decades have failed to reduce ARDS mortality. This short note recounts past data indicating that (i) neutrophils home along an IL-8 gradient, (ii) in ARDS, massive neutrophil accumulation and degranulation in and along bronchoalveolar spaces contributes to damage and hypoxia, (iii) large increases in IL-8 are one of the chemotaxic signals drawing neutrophils to the ARDS lung, and (iv) old data from dermatology and glioblastoma research showed that the old drug against Hansen's disease, dapsone, inhibits neutrophils' chemotaxis to IL-8. Therefore dapsone might lower neutrophils' contributions to ARDS lung pathology. Dapsone can create methemoglobinemia that although rarely problematic it would be particularly undesirable in ARDS. The common antacid drug cimetidine lowers risk of dapsone related methemoglobinemia and should be given concomitantly.

Authors+Show Affiliations

IIAIGC Study center, Burlington, Vermont, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32286085

Citation

Kast, R E.. "Dapsone as Treatment Adjunct in ARDS." Experimental Lung Research, vol. 46, no. 5, 2020, pp. 157-161.
Kast RE. Dapsone as treatment adjunct in ARDS. Exp Lung Res. 2020;46(5):157-161.
Kast, R. E. (2020). Dapsone as treatment adjunct in ARDS. Experimental Lung Research, 46(5), 157-161. https://doi.org/10.1080/01902148.2020.1753266
Kast RE. Dapsone as Treatment Adjunct in ARDS. Exp Lung Res. 2020 May - Jun;46(5):157-161. PubMed PMID: 32286085.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dapsone as treatment adjunct in ARDS. A1 - Kast,R E, Y1 - 2020/04/14/ PY - 2020/4/15/pubmed PY - 2020/4/15/medline PY - 2020/4/15/entrez KW - ARDS KW - IL-8 KW - chemokine KW - dapsone SP - 157 EP - 161 JF - Experimental lung research JO - Exp. Lung Res. VL - 46 IS - 5 N2 - Multiple pharmacological interventions tested over the last decades have failed to reduce ARDS mortality. This short note recounts past data indicating that (i) neutrophils home along an IL-8 gradient, (ii) in ARDS, massive neutrophil accumulation and degranulation in and along bronchoalveolar spaces contributes to damage and hypoxia, (iii) large increases in IL-8 are one of the chemotaxic signals drawing neutrophils to the ARDS lung, and (iv) old data from dermatology and glioblastoma research showed that the old drug against Hansen's disease, dapsone, inhibits neutrophils' chemotaxis to IL-8. Therefore dapsone might lower neutrophils' contributions to ARDS lung pathology. Dapsone can create methemoglobinemia that although rarely problematic it would be particularly undesirable in ARDS. The common antacid drug cimetidine lowers risk of dapsone related methemoglobinemia and should be given concomitantly. SN - 1521-0499 UR - https://www.unboundmedicine.com/medline/citation/32286085/Dapsone_as_treatment_adjunct_in_ARDS L2 - http://www.tandfonline.com/doi/full/10.1080/01902148.2020.1753266 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.